A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the safety and tolerability of SH3765 in subjects with
advanced malignant tumor by determining the maximum tolerated dose (MTD) and recommended
Phase 2 dose (RP2D). The second objective is to evaluate the PK profile and preliminary
efficacy of SH3765 in subjects with advanced malignant tumor.